Last week we talked about biotech penny shares with upcoming catalysts. That article obtained numerous consideration and for apparent causes. As I defined, few industries will host corporations that may let you know after they’ve obtained information coming. Biotech is one in all these industries, and it makes for thrilling market circumstances. You’ve obtained the “buy the rumor, sell the news” pattern to navigate.
PennyStocks.com – PennyStocks
Then there’s the market shock the place corporations ship outcomes far surpassing what Wall Street initially thought. Something to recollect is that there are such a lot of completely different steps concerned in taking a biotech firm from pre-clinical to industrial levels. Each section presents a milestone alternative.
Biotech shares are thrilling to observe, particularly round these potential milestone occasions. These are all issues to remember, whether or not it’s an business presentation, new research knowledge, or one thing else.
- The Stock Market This Week
- Penny Stocks To Watch This Week
- Penny Stocks To Watch On September 27:
- Zynerba Pharmaceuticals Inc.
- Verastem Oncology Inc.
- Lineage Cell Therapeutics
- Penny Stocks To Watch On September 28:
- Rigel Pharmaceuticals Inc.
- Asensus Surgical Inc.
- 9 Meters Biopharma Inc.
- Penny Stocks To Watch On September 30:
- Arbutus Biopharma Corporation
- Penny Stocks to Watch At The End of Q3:
- CTI BioPharma Corp.
- ASLAN Pharmaceuticals
- Penny Stocks To Watch On October 1:
- Precigen Inc.
- Penny Stocks To Watch This Week
The Stock Market This Week
We’ve obtained a number of issues to remember within the inventory market this week. It’s the ultimate week of September, which suggests an finish to one of the difficult months within the inventory marketplace for 2021. It’s additionally the top of the third quarter. Over the final 12 months, corporations have reported actual dates and broad intervals.
“By the end of Q3” is one in all these broad timeframes. So at present, we’re going to have a look at 10 top penny stocks presumed to have one thing to take discover of this week. Will these occasions change into bullish or bearish catalysts? If you’re looking for penny stocks to purchase, I’ll go away that last choice as much as you. At the very least, you’re armed with information heading into the top of September and the top of Q3.
Penny Stocks To Watch This Week
|1. Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)||September 27, 2021|
|2. Verastem Oncology (NASDAQ:VSTM)||September 27, 2021|
|3. Lineage Cell Therapeutics, Inc. (NYSE:LCTX)||September 27, 2021|
September 30, 2021
|4. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)||September 28, 2021|
|5. Asensus Surgical Inc. (NYSE:ASXC)||September 28, 2021|
|6. 9 Meters Biopharma Inc. (NASDAQ:NMTR)||September 28, 2021|
|7. Arbutus Biopharma Corporation (NASDAQ:ABUS)||September 30, 2021|
|8. CTI BioPharma Corp. (NASDAQ:CTIC)||Q3 2021|
|9. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)||Q3 2021|
|10. Precigen Inc. (NASDAQ:PGEN)||October 1, 2021|
Penny Stocks To Watch On September 27:
Zynerba Pharmaceuticals Inc.
Zynerba is likely one of the firm’s we mentioned final week on a list of penny stocks analysts say to buy right now. H.C. Wainwright analyst Oren Livnat reiterated the agency’s Buy ranking on ZYNE inventory and a worth goal of $9. Other than that, there are different extra scientific issues to think about when Zynerba. The firm focuses on transdermal therapies for uncommon and near-rare issues.
It made a number of displays this month on its ZYN002 platform, trademarked as Zygel. This product is a transdermal gel administered to kids with developmental and epileptic encephalopathy. Recent outcomes of ongoing research have demonstrated how Zygel can profit sufferers even throughout longer-term time frames. Patients with Autism Spectrum Disorder who accomplished a 38-week therapy confirmed “statistically significant improvements” in comparison with baselines within the research.
What To Watch With ZYNE Stock This Week
As you’ll come to search out, the Cantor Global Healthcare Conference shall be a degree of focus for a lot of corporations this week. The convention goes from September 27 – September 30. On September twenty seventh, Zynerba’s CEO Armando Anido begins his presentation at 11:20 AM ET. Keep this in thoughts if ZYNE is in your listing of penny shares this week.
Verastem Oncology Inc.
Another one of many corporations that we’ve incessantly mentioned this month is Verastem. Not solely was it highlighted for bullish analyst sentiment, but it surely was additionally spotlighted for a biotech occasion final week. Verastem introduced that research knowledge in a mixture of its VS-6766 and defactinib demonstrated potential in treating ovarian most cancers. The firm mentioned that the median progression-free survival throughout all sufferers was 23 months.
In addition to those outcomes, Verastem additionally introduced a medical collaboration settlement with Amgen (NASDAQ:AMGN), evaluating a mixture of VS-6766 with Amgen’s sotorasib, trademarked as LUMAKRAS, in sufferers with non-small cell lung most cancers. This trial is anticipated to start by the top of the yr. So that could possibly be one thing to remember in a while throughout This autumn.
What To Watch With VSTM Stock This Week
Similar to Zynerba, VSTM inventory shall be in focus this week as administration presents on the Cantor Conference. September 27 can even be the date to remember right here. The firm begins its presentation at 4 PM ET.
Lineage Cell Therapeutics
Similar to Rigel, the final yr was a pivotal one for progress in Lineage Cell Therapeutics. Last September, shares of LCTX inventory traded beneath $1. Heading into this week, they’re firmly buying and selling above $2. Here’s what’s gone on with Lineage and why this week could possibly be essential for the corporate.
Lineage focuses on allogeneic cell therapies for issues like dry age-related macular degeneration (AMD). Its OpRegen therapy is being studied for this indication in ongoing section trials, having already demonstrated enhancements in research sufferers. The firm can also be creating OPC1 for subacute spinal wire accidents and VAC2 to deal with non-small cell lung most cancers.
What To Watch With LCTX Stock This Week
Lineage is dealing with double-duty this week. The first date to markdown is September 27. Company CEO Brian Culley begins presenting at a fireplace chat throughout the Cantor Healthcare convention at 4 PM ET. Later this week, up to date interim outcomes from its Phase 1/2a research of OpRegen® shall be featured in a podium presentation on the 54th Annual Scientific Meeting of the Retina Society. This presentation begins on September 30 at 9:52 AM EDT.
Penny Stocks To Watch On September 28:
Rigel Pharmaceuticals Inc.
Despite September being a combined month for the corporate’s shares, Rigel has skilled important progress over the past yr. This time in 2020, shares of RIGL inventory have been buying and selling barely larger than $2. Heading into this week, the inventory is buying and selling marginally decrease than $4.
The biotech firm develops small molecule medication for treating hematologic issues, most cancers, and uncommon immune ailments. The firm’s first FDA-approved product, TAVALISSE (fostamatinib disodium hexahydrate), is utilized in treating power immune thrombocytopenia. Fostamatinib can also be being studied in a number of medical trials for treating anemia in addition to COVID-19. The latter has helped deliver a few of the “hype” issue into the combination this yr, because of elevated consideration on COVID shares.
Earlier this month, the outcomes from a Phase 2 trial evaluating fostamatinib for hospitalized COVID sufferers have been printed in Clinical Infectious Diseases. Data confirmed that therapy with fostamatinib was properly tolerated and related to clinically significant enchancment in outcomes of hospitalized sufferers.
What To Watch With RIGL Stock This Week
Once once more, business conferences are the main target. This week Rigel’s Raul Rodriguez presents an organization overview at Cantors Global Healthcare Conference. Suppose RIGL inventory is in your listing, markdown September 28 at 4:40 PM ET. Rodriguez begins his presentation at the moment.
Asensus Surgical Inc.
Shares of ASXC inventory began the yr sturdy. Since the beginning of April, the general pattern has been principally sideways. There was a short spike in June, however issues have subsided. One of the issues that proceed holding traders’ pursuits is the corporate’s medical system platform. Asensus’ Intelligent Surgical Unit (ISU) was designed to extend surgeon management and streamline surgical procedure experiences and outcomes. The firm’s utilization of machine imaginative and prescient and augmented intelligence has introduced a brand new layer of know-how into the working room.
Earlier this month, its ISU system obtained FDA 510(ok) clearance to develop machine imaginative and prescient capabilities. This is used with the corporate’s Senhance Surgical System enabling digital laparoscopy.
What To Watch With ASXC Stock This Week
This week Asensus continues its business presentation circuit. The third and last presentation shall be at, you guessed it, the Cantor Healthcare Conference. Company CEO Anthony Fernando and CFO Shameze Rampertab start their presentation at 1:20 PM ET on September 28.
9 Meters Biopharma Inc.
The previous few weeks for9 Meters Biopharma have been sturdy. Shares of NMTR inventory moved up from round $1 in mid-August to over $1.30 final week. Helping enhance sentiment was a mixture of extra strong earnings outcomes and new offers contributing to advancing the corporate’s therapy pipeline.
In explicit, 9 Meters introduced a collaboration with the European Biomedical Research Institute of Salerno, Italy (EBRIS). This was to check the corporate’s larazotide to deal with multisystem inflammatory syndrome in kids (MIS-C). Larazotide can also be in Phase 3 medical improvement for adults with celiac illness. EBRIS plans to provoke a Phase 2a research in MIS-C in This autumn 2021.
Another aspect of this story bringing curiosity to NMTR inventory is analyst and insider sentiment. In September, Director Mark Sirgo and CFO Edward Sitar purchased a complete of 88,529 between common costs of $1.22 and $1.36. Sirgo accounted for the majority of that, with over 73,000 shares bought at a mean worth of $1.36, bringing his immediately managed place to over 1.1 million shares. Analysts at BMO Capital are additionally bullish proper now. The agency has an Outperform ranking on the inventory and a $5 worth goal.
What To Watch This Week With NMTR Stock
Similar to Asensus, 9 Meters is buttoning up a circuit of displays this week. CEO John Temperato presents at Cantor’s Healthcare Conference on September 28, starting at 4:40 PM ET.
Penny Stocks To Watch On September 30:
Arbutus Biopharma Corporation
Shares of Arbutus have been crimson scorching over the previous few months. Beginning in August, ABUS inventory began its climb, benefiting from extra strong gross sales ends in the second quarter along with an upbeat outlook from administration regarding Arbutus’ therapy pipeline.
William Collier, President and Chief Executive Officer of Arbutus, defined, “We had a productive second quarter, particularly in advancing our efforts to position AB-729 as a potential cornerstone therapy in future HBV combination regimens. Our recently announced proof-of-concept clinical collaborations with Vaccitech plc and Antios Therapeutics, Inc. to evaluate AB-729 with other agents reflects this objective, as does our planned Phase 2a clinical trial to evaluate AB-729 in combination with Peg-IFNα-2a.”
Plenty of the main target has been on Arbutus versus Moderna, consider it or not. The two conflicted over Arbutus’s lipid formulations for nucleic acid supply. Earlier this month, the European Patent Office mentioned that its 069 patent associated to lipid formulations was “Inventive” (legitimate). It was in settlement with the US Patent and Trademark Office, which granted a discover of allowance this month. Moderna is shifting ahead with an enchantment set for a listening to subsequent month. However, if Arbutus is right, it may open the doorways for eligibility to obtain royalties from Moderna’s COVID-19 vaccine gross sales.
What To Watch With ABUS Stock This Week
The firm presents on the Cantor Global Healthcare Conference that many others on this listing of penny shares shall be in attendance this week. CEO William Collier will give the presentation starting at 8:40 AM ET. So if ABUS inventory is in your listing proper now, hold September thirtieth in thoughts.
Penny Stocks to Watch At The End of Q3:
CTI BioPharma Corp.
CTI Biopharma kicks off the part of this listing of penny shares that haven’t given particular dates. However, since that is the ultimate week of the third quarter, the countdown has begun for corporations like CTI to ship on their beforehand introduced plans.
The firm has targeted its efforts on advancing its focused therapy platform aimed toward blood-related cancers. It targets sufferers with myelofibrosis and extreme COVID-19 in response to the 2020/2021 pandemic. Its present pipeline therapy consists of pacritinib for treating myelofibrosis, which has a New Drug Application below evaluation by the FDA. There’s a Prescription Drug User Fee Act date of November thirtieth. So because the fourth quarter begins, that shall be an essential date to remember. Considering that the corporate has already began commercialization actions, CTI seems optimistic concerning the FDA’s potential choice. However, because the saying goes, they gained’t know until they know.
What To Watch With CTIC Stock This Week
This week could possibly be all about COVID 19 for CTI Biopharma. In its second-quarter monetary outcomes and enterprise replace, administration defined that they count on to ship interim evaluation from a Phase 3 PRE-VENT trial in hospitalized sufferers with extreme COVID-19 this quarter.
Another one of many “Q3 penny stocks to watch” is ASLAN Pharmaceuticals. The firm focuses on remedies for immune ailments. It’s at present evaluating a number of therapy candidates. Its ASLAN004 targets atopic dermatitis, and its ASLAN003 focuses on autoimmune illness.
What To Watch With ASLN Stock This Week
In June, the corporate accomplished the recruitment of 27 sufferers into the growth cohort of the double-blind placebo-controlled a number of ascending dose research. Topline knowledge is anticipated on the finish of this quarter, in accordance with the corporate’s August sixth replace. Something to consider is that earlier this yr, knowledge from a single ascending dose research demonstrated that ASLAN004 has a positive tolerability profile and potential as a unique therapy technique for atopic dermatitis. With the a number of ascending dose research yield the same response?
Penny Stocks To Watch On October 1:
On the upper finish of the penny inventory vary, Precigen shall be on the listing of penny shares to observe this week. But you’ll have to attend just a few days for its potential catalyst date. Something to know concerning the firm is that it’s labored diligently on advancing its gene and cell therapies with this yr as an essential one for the corporate.
Management elaborated on this in its newest quarterly enterprise replace. Helen Sabzevari, Ph.D., President, and CEO of Precigen, mentioned, “We see 2021 as a pivotal year for the UltraCAR-T, ActoBiotics, and AdenoVerse platforms with significant new clinical data on our most advanced therapeutic candidates from these core therapeutic platforms.”
What To Watch With PGEN Stock This Week
ActoBiotics is also called AG019 ActoBiotics, would be the focus this week. Additional knowledge from its AG019 Phase 1b/2a medical trial shall be introduced on October 1 at midday CET as an oral presentation on the European Association for the Study of Diabetes Meeting. The summary entitled, “AG019 ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and demonstrated encouraging metabolic and immunological effects” shall be introduced by Chantal Mathieu, MD, Ph.D., Professor of Medicine on the Katholieke Universiteit Leuven, Belgium. In addition, a medical trial assessing the efficacy of extended therapy of oral AG019 can also be deliberate.
Something to notice is that constructive topline knowledge from the AG019 Phase 1b/2a medical trial have been reported earlier this yr on the Federation of Clinical Immunology Societies Meeting. The main endpoints of security and tolerability for the Phase 1b AG019 monotherapy and the Phase 2a AG019 mixture remedy have been met. No severe hostile occasions have been reported both.
Penny Stocks To Watch This Week
There are many biotech penny shares to observe this week, together with those talked about on this article. Keep in thoughts that simply because the corporate has beforehand introduced a date, that doesn’t imply information launched shall be constructive (or detrimental, for that matter). However, what it does imply is that there could possibly be new information to consider. With that may come loads of volatility and, if favorable, alternatives to capitalize. Will that be the case this week?